Scholar Rock's Drug Helps Patients on Zepbound Preserve Muscle in Trial
June 18 (Reuters) - Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound.
Shares of Scholar Rock jumped 13.8% in premarket trading.
Scholar's drug, apitegromab, when combined with Zepbound preserved an additional 1.9 kilograms of lean mass when compared with Zepbound alone.
Patients who took the drugs in combination also lost more fat mass than those on Zepbound alone.
Earlier this month, Regeneron said its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10